When we restricted our analyses to women with hormone receptor-positive breast cancer only (defined as any ER- or PR-positive), our estimates became less precise but were similar in effect size, and most interactions persisted (Additional file 3: Table S3). This evidence concerns the gene ESR1 and breast carcinoma.